S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Gilead Sciences, Inc.

GILD · Healthcare · · USD
151.00 USD
0.00 (-0.15%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score STRONG BUY Mid-term (Position)

80
/ 100
Technical 100
Trend & RS 95
Momentum 71
Fundamental 56
Macro 64
Liquidity 56
ComponentScoreWeight
Technical 100.0 20%
Trend & RS 95.2 30%
Momentum 71.2 15%
Fundamental 55.6 10%
Macro 64.4 20%
Liquidity 55.7 5%

Trade Setup

Entry 151.00
Stop Loss 143.76 (4.8%)
Target 1 (1:1) 158.24 (+4.8%)
Target 2 (2:1) 165.48 (+9.6%)
ATR(14) 3.62 (2.4%)
Risk per Share 7.24
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 28.1 -0.88
Momentum 71.2 +0.85
Quality 7.3 -1.71
Composite 35.5

Quality Scores

Piotroski F-Score 1 /9 — Weak
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 5.95 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 15.8 4.0 Above
Dividend Yield 2.2% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
51.79%
Full Kelly
25.89%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 80/100. Estimated win rate 64%, avg win 9.8%, avg loss 3.4%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

4
Bullish Signals
0
Bearish Signals
67.71
RSI(14)
4.3363
MACD

Relative Strength (RS) IMPROVING

87
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+13.0% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High Near 3-month high 3d since high
Sector Outperformance +9.9% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 67.71 NEUTRAL
Macd 4.3363 BULLISH
Ma Cross 136.6 / 133.37 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 1.15x NORMAL

Key Levels

LevelPrice
52-Week High157.29
Bollinger Upper155.66
SMA(200)133.37
SMA(50)136.6
SMA(20)144.35
Current Price151.00
Bollinger Lower133.04
52-Week Low108.46
ATR(14)3.62

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.23x Normal bar — no special VSA pattern
2026-09-01 Normal 0.91x Normal bar — no special VSA pattern
2026-09-02 Normal 0.92x Normal bar — no special VSA pattern
2026-09-03 Normal 0.84x Normal bar — no special VSA pattern
2026-09-04 Normal 1.15x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 147.87 Above Kijun
Kijun-sen (26) 140.66 Base line
Senkou A 144.26 Leading span A
Senkou B 138.11 Leading span B
Cloud 138.11 – 144.26 Bullish (Green)
Price vs Cloud 151.00 Above Cloud
Chikou Span 130.21 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 133.04 – 155.66  |  KC: 139.03 – 149.67

Divergences (last 60 bars)

No significant divergences detected in the last 60 bars.

Anchored VWAP

VWAP: 130.65 Anchor: 2025-10-02 (52w Low) ABOVE AVWAP +15.6%

Heikin-Ashi Trend

BULLISH Full data via /api/advanced/GILD

Valuation

MetricValue
Market Cap187.23B
P/E (TTM)N/A
Forward P/EN/A
P/B15.84
EPS-2.66

Financial Health

MetricValue
Revenue Growth10.2%
Profit Margin-10.6%
ROE-20.7%
Debt/Equity223.47
Current Ratio1.26
Dividend Yield2.2%
Payout RatioN/A
Beta0.35

Trading Data

151.00
Open
151.00
Day High
151.00
Day Low
6.18M
Volume (0.9x avg)

Recent News (8)

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
24/7 Wall St. · 2026-09-07
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Motley Fool · 2026-09-05
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Simply Wall St. · 2026-09-04
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Zacks · 2026-09-04
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
24/7 Wall St. · 2026-09-04
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
Pharma Voice · 2026-09-04
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Zacks · 2026-09-03
Is Gilead Sciences Stock Outperforming the S&P 500?
Barchart · 2026-09-03

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —